SOPHiA GENETICS Q2 Revenue Jumps 27%, Raises Full-Year Guidance
SOPH has more than doubled off its 52-week low of $2.92.
Summary
SOPHiA GENETICS reported Q2 revenue of $23.3M, a 27% year-over-year increase, driven by 80% growth in its Liquid Biopsy segment and 60% U.S. volume growth. The company raised its full-year 2026 revenue guidance to $94-96M from $92-94M and now expects an adjusted EBITDA loss of $29-32M, approaching breakeven by year-end. This follows a $57.5M public offering in June and a leadership transition completed in late June. The strong top-line beat and guidance raise signal accelerating commercial traction, particularly in oncology diagnostics. New companion diagnostic programs with AstraZeneca add to the biopharma partnership momentum.
At the time of this announcement, SOPH was trading at $5.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $477.4M. The 52-week trading range was $2.92 to $6.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.